TP53 and endometrial cancer: Five pathologists with varying levels of experience and exposure to gynecologic malignancies, ranging from residents in training (4th year) to those with more than 20 years of practice at a university hospital, independently evaluated p53 IHC in 98 endometrial cancer biopsy samples and 86 endometrial cancer hysterectomy samples.